Peptides Similar to Linaclotide
Compare Linaclotide with related peptides and alternatives
📌TL;DR
- •1 similar peptides identified
- •Larazotide: Low - Both are gut-acting peptides, but larazotide targets tight junction permeability for celiac disease while linaclotide targets GC-C for IBS-C/CIC
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Linaclotide (current) | - | - |
| Larazotide | Low - Both are gut-acting peptides, but larazotide targets tight junction permeability for celiac disease while linaclotide targets GC-C for IBS-C/CIC | Completely different mechanisms and indications. Larazotide is a tight junction regulator for celiac disease. Linaclotide is a GC-C agonist for IBS-C and constipation. |
Peptides Related to Linaclotide#
Linaclotide is the first-in-class guanylate cyclase-C (GC-C) agonist for IBS-C and chronic constipation. As a gut-restricted cyclic peptide with both secretory and analgesic properties, it occupies a unique position in the treatment landscape. The most relevant comparison is with plecanatide (another GC-C agonist), followed by non-peptide agents used for similar indications.
Plecanatide (Trulance)#
Plecanatide is a 16-amino-acid synthetic peptide analog of uroguanylin, the second FDA-approved GC-C agonist. It was developed by Synergy Pharmaceuticals and approved in 2017 for CIC and in 2018 for IBS-C.
Mechanism comparison: Both linaclotide and plecanatide activate GC-C to increase cGMP, promote chloride/water secretion, and reduce visceral pain. The key difference is that plecanatide was designed with pH-dependent activation -- it has enhanced binding affinity at pH 5 (matching the proximal duodenum) and reduced activity at neutral pH. Linaclotide has pH-independent activity throughout the intestine.
Clinical efficacy: Both agents have demonstrated efficacy for IBS-C and CIC in phase 3 trials. No head-to-head trial exists. Cross-trial comparisons suggest similar effect sizes, though direct comparison is limited by differences in trial design and endpoint definitions.
Dosing: Plecanatide is dosed at 3 mg once daily for both IBS-C and CIC (simpler dosing). Linaclotide uses 290 mcg for IBS-C and 145 mcg (or 72 mcg) for CIC.
Safety: Both have diarrhea as the primary adverse effect and carry the same pediatric boxed warning. Diarrhea rates may be slightly lower with plecanatide, though cross-trial comparisons are unreliable.
| Parameter | Linaclotide | Plecanatide |
|---|---|---|
| Peptide length | 14 amino acids | 16 amino acids |
| Parent molecule | STa/guanylin | Uroguanylin |
| pH dependence | Independent | Enhanced at pH 5 |
| IBS-C dose | 290 mcg daily | 3 mg daily |
| CIC dose | 145 mcg (or 72 mcg) daily | 3 mg daily |
| FDA approval | 2012 | 2017 (CIC), 2018 (IBS-C) |
| Diarrhea rate | 16-20% | ~5-8% (cross-trial) |
| Market experience | Since 2012 | Since 2017 |
Lubiprostone (Amitiza)#
Lubiprostone is a bicyclic fatty acid (not a peptide) that activates ClC-2 chloride channels on the apical surface of intestinal epithelial cells. FDA-approved for CIC (2006), IBS-C in women (2008), and opioid-induced constipation (2013).
Mechanism comparison: Lubiprostone acts on a different chloride channel (ClC-2) than linaclotide (CFTR via GC-C). It does not produce the extracellular cGMP that mediates linaclotide's visceral pain reduction. Thus, lubiprostone primarily addresses constipation without the analgesic component important for IBS-C.
Key trade-off: Linaclotide offers the dual benefit of secretory and analgesic effects, while lubiprostone has broader indications (including OIC) and twice-daily dosing flexibility but lacks the pain reduction mechanism.
Tegaserod (Zelnorm)#
Tegaserod is a 5-HT4 receptor agonist re-approved in 2019 for IBS-C in women under 65 without cardiovascular risk factors. It acts systemically by stimulating peristalsis and intestinal secretion through serotonin receptor activation.
Key difference: Tegaserod is a systemically absorbed small molecule with cardiovascular safety restrictions (originally withdrawn due to CV events), while linaclotide is a gut-restricted peptide with no systemic safety concerns.
Summary Comparison#
| Feature | Linaclotide | Plecanatide | Lubiprostone |
|---|---|---|---|
| Drug class | GC-C agonist peptide | GC-C agonist peptide | ClC-2 activator |
| Route | Oral (once daily) | Oral (once daily) | Oral (twice daily) |
| Systemic absorption | Negligible | Negligible | Low but measurable |
| IBS-C pain benefit | Yes (cGMP-mediated) | Yes (cGMP-mediated) | No |
| Indications | IBS-C, CIC | IBS-C, CIC | IBS-C (women), CIC, OIC |
| Pediatric warning | Boxed warning (<2 yr) | Boxed warning (<2 yr) | Not indicated |
| FDA approval | 2012 | 2017-2018 | 2006-2013 |
Related Reading#
Frequently Asked Questions About Linaclotide
What are the main alternatives to Linaclotide?
The primary alternatives to Linaclotide include Larazotide. Each has a different mechanism of action and evidence profile. The choice between them depends on the specific research objectives.
How does Linaclotide compare to Larazotide?
Low - Both are gut-acting peptides, but larazotide targets tight junction permeability for celiac disease while linaclotide targets GC-C for IBS-C/CIC. Key differences: Completely different mechanisms and indications. Larazotide is a tight junction regulator for celiac disease. Linaclotide is a GC-C agonist for IBS-C and constipation.. Advantages of Larazotide: Established FDA-approved therapy with proven efficacy for both constipation and visceral pain in IBS-C. Disadvantages: Not effective for celiac disease or intestinal permeability disorders.
Can Linaclotide be combined with other peptides?
Some research protocols study Linaclotide in combination with related peptides such as Larazotide. However, combination studies are limited and no established guidelines exist for combining these peptides. Any combination use should be guided by available research data.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer